Franklin Resources Inc. Has $2.18 Million Stake in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)

Franklin Resources Inc. increased its stake in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) by 83.0% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 66,461 shares of the biopharmaceutical company's stock after purchasing an additional 30,144 shares during the period. Franklin Resources Inc. owned approximately 0.12% of Agios Pharmaceuticals worth $2,184,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also recently added to or reduced their stakes in the company. Vanguard Group Inc. grew its holdings in shares of Agios Pharmaceuticals by 1.5% during the fourth quarter. Vanguard Group Inc. now owns 5,631,321 shares of the biopharmaceutical company's stock worth $185,045,000 after buying an additional 85,339 shares in the last quarter. State Street Corp raised its holdings in shares of Agios Pharmaceuticals by 10.2% in the third quarter. State Street Corp now owns 2,331,433 shares of the biopharmaceutical company's stock valued at $103,586,000 after purchasing an additional 216,484 shares during the last quarter. Geode Capital Management LLC lifted its position in shares of Agios Pharmaceuticals by 0.5% in the third quarter. Geode Capital Management LLC now owns 1,357,531 shares of the biopharmaceutical company's stock worth $60,326,000 after purchasing an additional 6,101 shares in the last quarter. Fisher Asset Management LLC boosted its holdings in Agios Pharmaceuticals by 12.3% during the fourth quarter. Fisher Asset Management LLC now owns 960,661 shares of the biopharmaceutical company's stock worth $31,567,000 after purchasing an additional 105,333 shares during the last quarter. Finally, Artisan Partners Limited Partnership grew its position in Agios Pharmaceuticals by 27.4% in the fourth quarter. Artisan Partners Limited Partnership now owns 499,134 shares of the biopharmaceutical company's stock valued at $16,402,000 after purchasing an additional 107,292 shares in the last quarter.

Analyst Ratings Changes

AGIO has been the subject of a number of recent research reports. StockNews.com downgraded shares of Agios Pharmaceuticals from a "hold" rating to a "sell" rating in a research note on Friday, February 14th. HC Wainwright initiated coverage on Agios Pharmaceuticals in a research report on Monday, February 24th. They set a "buy" rating and a $58.00 price target on the stock. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and five have given a buy rating to the stock. According to MarketBeat, the company currently has an average rating of "Hold" and an average price target of $56.57.

Insider Buying and Selling

In other Agios Pharmaceuticals news, Director Jacqualyn A. Fouse sold 7,497 shares of the firm's stock in a transaction that occurred on Thursday, April 10th. The shares were sold at an average price of $25.90, for a total transaction of $194,172.30. Following the completion of the sale, the director now directly owns 149,220 shares in the company, valued at $3,864,798. This trade represents a 4.78 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. 4.93% of the stock is currently owned by insiders.

Agios Pharmaceuticals Stock Up 1.9 %

Shares of NASDAQ AGIO traded up $0.52 during midday trading on Friday, hitting $27.66. 590,693 shares of the company's stock were exchanged, compared to its average volume of 711,909. The firm has a market capitalization of $1.58 billion, a PE ratio of 2.44 and a beta of 0.83. Agios Pharmaceuticals, Inc. has a 12 month low of $23.42 and a 12 month high of $62.58. The company's 50 day moving average price is $30.77 and its 200 day moving average price is $38.68.

Agios Pharmaceuticals (NASDAQ:AGIO - Get Free Report) last released its quarterly earnings data on Thursday, February 20th. The biopharmaceutical company reported ($1.74) EPS for the quarter, missing analysts' consensus estimates of ($1.69) by ($0.05). Agios Pharmaceuticals had a negative return on equity of 2.51% and a net margin of 1,845.92%. On average, equities research analysts anticipate that Agios Pharmaceuticals, Inc. will post -6.85 EPS for the current year.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.